Expression of nectin-4 in papillary renal cell carcinoma.
Nectin 4
Papillary renal cell carcinoma
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
22 Sep 2022
22 Sep 2022
Historique:
received:
08
06
2022
accepted:
13
09
2022
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
23
9
2022
Statut:
epublish
Résumé
Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. Enfortumab vedotin-ejf (EV) is an antibody drug conjugate that targets Nectin-4. The aim of our study was to investigate the expression of Nectin-4 in a large cohort of papillary RCC specimens. Specimens were derived from the PANZAR consortium (Erlangen, Heidelberg, Herne, Homburg, Mainz, Mannheim, Marburg, Muenster, LMU Munich, TU Munich, and Regensburg). Clinical data and tissue samples from n = 190 and n = 107 patients with type 1 and 2 pRCC, respectively, were available. Expression of Nectin-4 was determined by immunohistochemistry (IHC). In total, Nectin-4 staining was moderately or strongly positive in of 92 (48.4%) of type 1 and 39 (36.4%) type 2 of pRCC cases. No associations between Nectin-4 expression and age at diagnosis, gender, grading, and TNM stage was found. 5 year overall survival rate was not statistically different in patients with Nectin-4 negative versus Nectin-4 positive tumors for the overall cohort and the pRCC type 2 subgroup, but higher in patient with Nectin-4 positive pRCC type 1 tumors compared to Nectin-4 negative tumors (81.3% vs. 67.8%, p = 0.042). Nectin-4 could not be confirmed as a prognostic marker in pRCC in general. Due to its high abundance on pRCC specimens Nectin-4 is an interesting target for therapeutical approaches e.g. with EV. Clinical trials are warranted to elucidate its role in the pRCC treatment landscape.
Sections du résumé
BACKGROUND
BACKGROUND
Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. Enfortumab vedotin-ejf (EV) is an antibody drug conjugate that targets Nectin-4. The aim of our study was to investigate the expression of Nectin-4 in a large cohort of papillary RCC specimens.
PATIENTS AND METHODS
METHODS
Specimens were derived from the PANZAR consortium (Erlangen, Heidelberg, Herne, Homburg, Mainz, Mannheim, Marburg, Muenster, LMU Munich, TU Munich, and Regensburg). Clinical data and tissue samples from n = 190 and n = 107 patients with type 1 and 2 pRCC, respectively, were available. Expression of Nectin-4 was determined by immunohistochemistry (IHC).
RESULTS
RESULTS
In total, Nectin-4 staining was moderately or strongly positive in of 92 (48.4%) of type 1 and 39 (36.4%) type 2 of pRCC cases. No associations between Nectin-4 expression and age at diagnosis, gender, grading, and TNM stage was found. 5 year overall survival rate was not statistically different in patients with Nectin-4 negative versus Nectin-4 positive tumors for the overall cohort and the pRCC type 2 subgroup, but higher in patient with Nectin-4 positive pRCC type 1 tumors compared to Nectin-4 negative tumors (81.3% vs. 67.8%, p = 0.042).
CONCLUSION
CONCLUSIONS
Nectin-4 could not be confirmed as a prognostic marker in pRCC in general. Due to its high abundance on pRCC specimens Nectin-4 is an interesting target for therapeutical approaches e.g. with EV. Clinical trials are warranted to elucidate its role in the pRCC treatment landscape.
Identifiants
pubmed: 36136143
doi: 10.1007/s12672-022-00558-2
pii: 10.1007/s12672-022-00558-2
pmc: PMC9500133
doi:
Types de publication
Journal Article
Langues
eng
Pagination
90Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : ER 795/1-1
Organisme : Deutsche Gesellschaft für Urologie
ID : StS1/FE-13
Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2021 Jul 15;385(3):287
pubmed: 34260846
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Appl Immunohistochem Mol Morphol. 2021 Sep 1;29(8):619-625
pubmed: 33901032
Am J Surg Pathol. 2020 Jul;44(7):e47-e65
pubmed: 32251007
Cancer Cell Int. 2019 Apr 23;19:106
pubmed: 31043861
Clin Genitourin Cancer. 2021 Feb;19(1):53-59.e1
pubmed: 32778505
Pathologe. 2016 Jul;37(4):355-60
pubmed: 27271258
World J Urol. 2018 Dec;36(12):1913-1926
pubmed: 30123932
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Oncology. 2022;100(6):331-336
pubmed: 35168242
Urology. 2007 Feb;69(2):230-5
pubmed: 17275070
J Urol. 2010 Feb;183(2):460-6
pubmed: 20006851
Ann Oncol. 2017 Apr 1;28(4):769-776
pubmed: 27998973
Ann Surg Oncol. 2014 Dec;21 Suppl 4:S584-90
pubmed: 24743909
Cancer Res. 2015 Oct 1;75(19):4131-42
pubmed: 26282167
Medicine (Baltimore). 2019 Jul;98(27):e16309
pubmed: 31277173
Vascul Pharmacol. 2021 Oct;140:106865
pubmed: 33945869
Oncology. 2022;100(10):536-541
pubmed: 35760058
J Biol Chem. 2001 Nov 16;276(46):43205-15
pubmed: 11544254
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
Nat Rev Mol Cell Biol. 2008 Aug;9(8):603-15
pubmed: 18648374
Clin Cancer Res. 2014 Jul 1;20(13):3411-21
pubmed: 24658158
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Cancer Res. 2009 Aug 15;69(16):6694-703
pubmed: 19679554
J Clin Oncol. 2020 Apr 1;38(10):1041-1049
pubmed: 32031899
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Hum Pathol. 2022 Mar;121:1-10
pubmed: 34998840
Urol Int. 2022;106(11):1168-1176
pubmed: 35654002
PLoS One. 2017 Sep 21;12(9):e0184173
pubmed: 28934212
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497
Onco Targets Ther. 2016 Jan 06;9:183-90
pubmed: 26793002
Med Sci Monit. 2019 Dec 28;25:10089-10094
pubmed: 31883369
Hum Pathol. 2019 Jan;83:212-223
pubmed: 30121370
Front Med (Lausanne). 2019 Sep 13;6:200
pubmed: 31572728
Cancer. 1997 Dec 1;80(11):2109-19
pubmed: 9392333
J Exp Clin Cancer Res. 2015 Mar 28;34:30
pubmed: 25888293
Sci Rep. 2017 Nov 27;7(1):16424
pubmed: 29180625